Literature DB >> 20043104

Expression of alpha-, beta- and gamma-synuclein in colorectal cancer, and potential clinical significance in progression of the disease.

Qing Ye1, Ting-Feng Wang, Yuan-Fei Peng, Jing Xie, Bo Feng, Ming-Yuan Qiu, Liang-Hui Li, Ai-Guo Lu, Bing-Ya Liu, Min-Hua Zheng.   

Abstract

The synucleins (alpha-, beta- and gamma-synuclein) are a small, soluble, highly conserved group of neuronal proteins that attracted considerable attention due to their involvement in both neurodegenerative diseases and cancer. In this study, we examined the synuclein exprsssion in colorectal cancer (CRC) tissues, tumor-matched non-neoplastic adjacent tissues (NNAT), and CRC cell lines, and then investigated clinical significance of synucleins. By using semi-quantitative RT-PCR, synuclein mRNA expression was detected in eight CRC cell lines. It was much higher in CRC samples than in NNAT samples (P<0.05). The results of western blotting showed that the levels of synucleins protein expression in CRC cells approximately corresponded to the levels of synuclein mRNA expression. Immunohistochemical staining revealed that gamma-synuclein protein expression was up-regulated in CRC samples compared to NNAT samples (P=0.022), and was significantly correlated with clinical stage and lymph node involvement of CRC (P<0.05). Although, there was no significant difference in either alpha- or beta-synuclein protein expression between tumor and normal samples (P>0.05), often more than one form of synuclein was expressed in a tumor sample. More ratios of later stage and lymph node-positive tumors expressed a least one type of synuclein protein, and more ratios showed positive for either alpha or gamma-synuclein expression, as well as positive either for beta or gamma-synuclein in more ratios of lymph node-positive tumors. These results show that alpha-, beta- and gamma-synuclein are expressed in a high percentage of CRC. gamma-synuclein protein is valuable for evaluation of progression of CRC, and it is more sensitive to predict advanced stage and lymph node invasion by detection of gamma-synuclein protein combined with either alpha- or beta-synuclein protein or both than by detection of gamma-synuclein only.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20043104

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  13 in total

1.  Identification of genes regulated by the EWS/NR4A3 fusion protein in extraskeletal myxoid chondrosarcoma.

Authors:  Christine Filion; Yves Labelle
Journal:  Tumour Biol       Date:  2012-05-18

2.  α-Synuclein in the colon and premotor markers of Parkinson disease in neurologically normal subjects.

Authors:  Joong-Seok Kim; In-Seok Park; Hyung-Eun Park; Su-Young Kim; Jung A Yun; Chan Kwon Jung; Hye-Young Sung; Jin-Kwon Lee; Won-Kyung Kang
Journal:  Neurol Sci       Date:  2016-11-01       Impact factor: 3.307

3.  The role of alpha-synuclein in melanin synthesis in melanoma and dopaminergic neuronal cells.

Authors:  Tianhong Pan; Julie Zhu; Wen-Jen Hwu; Joseph Jankovic
Journal:  PLoS One       Date:  2012-09-19       Impact factor: 3.240

4.  Metabolites of purine nucleoside phosphorylase (NP) in serum have the potential to delineate pancreatic adenocarcinoma.

Authors:  Shaiju K Vareed; Vadiraja B Bhat; Christopher Thompson; Vihas T Vasu; Damian Fermin; Hyungwon Choi; Chad J Creighton; Sitaram Gayatri; Ling Lan; Nagireddy Putluri; Gagan Singh Thangjam; Punit Kaur; Mohsen Shabahang; Judith G Giri; Alexey I Nesvizhskii; Alexander A A Asea; Anil G Cashikar; Arundhati Rao; James McLoughlin; Arun Sreekumar
Journal:  PLoS One       Date:  2011-03-23       Impact factor: 3.240

5.  α-Synuclein expression selectively affects tumorigenesis in mice modeling Parkinson's disease.

Authors:  Eitan Israeli; Eugenia Yakunin; Yonaton Zarbiv; Amir Hacohen-Solovich; Haya Kisos; Virginie Loeb; Michal Lichtenstein; Tziona Ben-Gedalya; Ofra Sabag; Eli Pikarsky; Haya Lorberboum-Galski; Ronit Sharon
Journal:  PLoS One       Date:  2011-05-18       Impact factor: 3.240

6.  Adeno-associated virus-delivered alpha synuclein inhibits bladder cancer growth via the p53/p21 signaling pathway.

Authors:  Zhengcun Wu; Chengxing Xia; Chao Zhang; Donghong Tang; Feineng Liu; Yitian Ou; Jiahong Gao; Hongkun Yi; Delin Yang; Kaili Ma
Journal:  Cancer Gene Ther       Date:  2022-01-21       Impact factor: 5.854

7.  Synuclein-γ (SNCG) expression in ovarian cancer is associated with high-risk clinicopathologic disease.

Authors:  Anna Strohl; Kristina Mori; Stacey Akers; Wiam Bshara; Barbara Buttin; Peter J Frederick; Irene B Helenowski; Carl D Morrison; Kunle Odunsi; Julian C Schink; Denise M Scholtens; Jian-Jun Wei; J Julie Kim
Journal:  J Ovarian Res       Date:  2016-11-03       Impact factor: 4.234

8.  Tristetraprolin inhibits mitochondrial function through suppression of α-Synuclein expression in cancer cells.

Authors:  Mai-Tram Vo; Seong Hee Choi; Ji-Heon Lee; Chung Hwan Hong; Jong Soo Kim; Unn Hwa Lee; Hyung-Min Chung; Byung Ju Lee; Jeong Woo Park; Wha Ja Cho
Journal:  Oncotarget       Date:  2017-06-27

Review 9.  mTOR-Rictor-EGFR axis in oncogenesis and diagnosis of glioblastoma multiforme.

Authors:  M Janaki Ramaiah; K Rohil Kumar
Journal:  Mol Biol Rep       Date:  2021-06-16       Impact factor: 2.316

10.  CILP2 overexpression correlates with tumor progression and poor prognosis in patients with colorectal cancer in The Cancer Genome Atlas (TCGA) study.

Authors:  Feng Huang; Yuanfei Peng; Qing Ye; Jinhu Chen; Yangming Li; Shengyuan Liu; Yangmei Xu; Lijie Huang
Journal:  World J Surg Oncol       Date:  2020-10-24       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.